{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:19:07Z","timestamp":1788787147273,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Spinal metastases (SM) are a\u00a0common radiotherapy (RT) indication. There is limited level\u00a0I\u00a0data to drive decision making regarding dose regimen (DR) and target volume definition (TVD). We aim to depict the patterns of care for RT of SM among German Society for Radiation Oncology (DEGRO) members.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>An online survey on conventional RT and Stereotactic Body Radiation Therapy (SBRT) for SM, distributed via e\u2011mail to all DEGRO members, was completed by 80\u00a0radiation oncologists between February\u00a024 and April\u00a029, 2022. Participation was voluntary and anonymous.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A\u00a0variety of DR was frequently used for conventional RT (primary: <jats:italic>n<\/jats:italic>\u202f=\u200915, adjuvant: <jats:italic>n<\/jats:italic>\u202f=\u200914). 30\u202fGy\/10 fractions was reported most frequently. TVD in adjuvant RT was heterogenous, with a\u00a0trend towards larger volumes. SBRT was offered in 65% (primary) and 21% (adjuvant) of participants\u2019 institutions. A\u00a0variety of DR was reported (primary: <jats:italic>n<\/jats:italic>\u202f=\u200940, adjuvant: <jats:italic>n<\/jats:italic>\u202f=\u200927), most commonly 27\u202fGy\/3 fractions and 30\u202fGy\/5 fractions. 59% followed International Consensus Guidelines (ICG) for TVD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We provide a\u00a0representative depiction of RT practice for SM among DEGRO members. DR and TVD are heterogeneous. SBRT is not comprehensively practiced, especially in the adjuvant setting. Further research is needed to provide a\u00a0solid data basis for detailed recommendations.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00066-023-02082-w","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T15:01:42Z","timestamp":1685977302000},"page":"159-174","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Radiotherapy concepts for spinal metastases\u2014results from an online survey among radiation oncologists of the German Society for Radiation Oncology"],"prefix":"10.1007","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8064-0010","authenticated-orcid":false,"given":"Maria","family":"Waltenberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco M. E.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"M\u00fcnch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Dobiasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin J.","family":"Redmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon S.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcliz","family":"Acker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Fehlings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Ringel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vajkoczy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie E.","family":"Combs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"key":"2082_CR1","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1016\/j.ejca.2010.04.025","volume":"46","author":"R Harel","year":"2010","unstructured":"Harel\u00a0R, Angelov\u00a0L (2010) Spine metastases: current treatments and future directions. Eur J Cancer 46:2696\u20132707. https:\/\/doi.org\/10.1016\/j.ejca.2010.04.025","journal-title":"Eur J Cancer"},{"key":"2082_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.prro.2016.08.001","volume":"7","author":"S Lutz","year":"2017","unstructured":"Lutz\u00a0S, Balboni\u00a0T, Jones\u00a0J et al (2017) Palliative radiation therapy for bone metastases: update of an ASTRO evidence-based guideline. Pract Radiat Oncol 7:4\u201312. https:\/\/doi.org\/10.1016\/j.prro.2016.08.001","journal-title":"Pract Radiat Oncol"},{"key":"2082_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.radonc.2022.05.024","volume":"173","author":"J van der Velden","year":"2022","unstructured":"van der Velden\u00a0J, Willmann\u00a0J, Spa\u0142ek\u00a0M et\u00a0al (2022) ESTRO ACROP guidelines for external beam radiotherapy of patients with uncomplicated bone metastases. Radiother Oncol 173:197\u2013206. https:\/\/doi.org\/10.1016\/j.radonc.2022.05.024","journal-title":"Radiother Oncol"},{"key":"2082_CR4","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1080\/14737140.2018.1493381","volume":"18","author":"BA Vellayappan","year":"2018","unstructured":"Vellayappan\u00a0BA, Chao\u00a0ST, Foote\u00a0M et\u00a0al (2018) The evolution and rise of stereotactic body radiotherapy (SBRT) for spinal metastases. Expert Rev Anticancer Ther 18:887\u2013900. https:\/\/doi.org\/10.1080\/14737140.2018.1493381","journal-title":"Expert Rev Anticancer Ther"},{"key":"2082_CR5","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1470-2045(21)00196-0","volume":"22","author":"A Sahgal","year":"2021","unstructured":"Sahgal\u00a0A, Myrehaug\u00a0SD, Siva\u00a0S et al (2021) Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2\/3 trial. Lancet Oncol 22:1023\u20131033. https:\/\/doi.org\/10.1016\/S1470-2045(21)00196-0","journal-title":"Lancet Oncol"},{"key":"2082_CR6","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma\u00a0DA, Olson\u00a0R, Harrow\u00a0S et al (2020) Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J\u00a0Clin Oncol 38:2830\u20132838. https:\/\/doi.org\/10.1200\/JCO.20.00818","journal-title":"J Clin Oncol"},{"key":"2082_CR7","volume-title":"S3-Leitlinie Supportive Therapie bei onkologischen PatientInnen","author":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF)","year":"2017","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF) (2017) S3-Leitlinie Supportive Therapie bei onkologischen PatientInnen"},{"key":"2082_CR8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/1471-2407-12-305","volume":"12","author":"DA Palma","year":"2012","unstructured":"Palma\u00a0DA, Haasbeek\u00a0CJA, Rodrigues\u00a0GB et al (2012) Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial. BMC Cancer 12:305. https:\/\/doi.org\/10.1186\/1471-2407-12-305","journal-title":"BMC Cancer"},{"key":"2082_CR9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00066-009-2044-2","volume":"185","author":"R Souchon","year":"2009","unstructured":"Souchon\u00a0R, Wenz\u00a0F, Sedlmayer\u00a0F et\u00a0al (2009) DEGRO practice guidelines for palliative radiotherapy of metastatic breast cancer. Strahlenther Onkol 185:417\u2013424. https:\/\/doi.org\/10.1007\/s00066-009-2044-2","journal-title":"Strahlenther Onkol"},{"key":"2082_CR10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.clon.2011.11.004","volume":"24","author":"E Chow","year":"2012","unstructured":"Chow\u00a0E, Zeng\u00a0L, Salvo\u00a0N et\u00a0al (2012) Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol 24:112\u2013124. https:\/\/doi.org\/10.1016\/j.clon.2011.11.004","journal-title":"Clin Oncol"},{"key":"2082_CR11","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.ijrobp.2009.10.073","volume":"79","author":"D Rades","year":"2011","unstructured":"Rades\u00a0D, Lange\u00a0M, Veninga\u00a0T et al (2011) Final results of a\u00a0prospective study comparing the local control of short-course and long-course radiotherapy for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys 79:524\u2013530. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.10.073","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2082_CR12","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00066-022-01938-x","volume":"198","author":"MD Piroth","year":"2022","unstructured":"Piroth\u00a0MD, Krug\u00a0D, Feyer\u00a0P et\u00a0al (2022) Oligometastasis in breast cancer\u2014current status and treatment options from a\u00a0radiation oncology perspective. Strahlenther Onkol 198:601\u2013611. https:\/\/doi.org\/10.1007\/s00066-022-01938-x","journal-title":"Strahlenther Onkol"},{"key":"2082_CR13","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.radonc.2018.04.030","volume":"128","author":"T Sprave","year":"2018","unstructured":"Sprave\u00a0T, Verma\u00a0V, F\u00f6rster\u00a0R et al (2018) Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy. Radiother Oncol 128:274\u2013282. https:\/\/doi.org\/10.1016\/j.radonc.2018.04.030","journal-title":"Radiother Oncol"},{"key":"2082_CR14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.prro.2013.05.001","volume":"4","author":"S Ryu","year":"2014","unstructured":"Ryu\u00a0S, Pugh\u00a0SL, Gerszten\u00a0PC et\u00a0al (2014) RTOG 0631 phase 2\/3\u00a0study of image guided stereotactic radiosurgery for localized (1\u20133) spine metastases: phase 2 results. Pract Radiat Oncol 4:76\u201381. https:\/\/doi.org\/10.1016\/j.prro.2013.05.001","journal-title":"Pract Radiat Oncol"},{"key":"2082_CR15","doi-asserted-by":"publisher","first-page":"e597","DOI":"10.1016\/j.ijrobp.2012.03.009","volume":"83","author":"BW Cox","year":"2012","unstructured":"Cox\u00a0BW, Spratt\u00a0DE, Lovelock\u00a0M et\u00a0al (2012) International spine radiosurgery consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 83:e597\u2013e605. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.03.009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2082_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijrobp.2016.09.014","volume":"97","author":"KJ Redmond","year":"2017","unstructured":"Redmond\u00a0KJ, Robertson\u00a0S, Lo\u00a0SS et\u00a0al (2017) Consensus contouring guidelines for postoperative stereotactic body radiation therapy for metastatic solid tumor malignancies to the spine. Int J Radiat Oncol Biol Phys 97:64\u201374. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.09.014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2082_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.radonc.2019.11.026","volume":"145","author":"EM Dunne","year":"2020","unstructured":"Dunne\u00a0EM, Sahgal\u00a0A, Lo\u00a0SS et\u00a0al (2020) International consensus recommendations for target volume delineation specific to sacral metastases and spinal stereotactic body radiation therapy (SBRT). Radiother Oncol 145:21\u201329. https:\/\/doi.org\/10.1016\/j.radonc.2019.11.026","journal-title":"Radiother Oncol"},{"key":"2082_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-12-530","volume":"12","author":"M Guckenberger","year":"2012","unstructured":"Guckenberger\u00a0M, Hawkins\u00a0M, Flentje\u00a0M, Sweeney\u00a0RA (2012) Fractionated radiosurgery for painful spinal metastases: DOSIS\u2014a\u00a0phase II trial. BMC Cancer 12:1\u20139. https:\/\/doi.org\/10.1186\/1471-2407-12-530","journal-title":"BMC Cancer"},{"key":"2082_CR19","unstructured":"Semrau S, Fietkau R Efficacy of dose intensified radiotherapy of spinal metastases by hypofractionated radiation and IGRT hfSRT mediated boost (SPIN-MET). https:\/\/clinicaltrials.gov\/show\/NCT01849510. Accessed: 02.02.2023"},{"key":"2082_CR20","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1016\/j.ijrobp.2010.04.026","volume":"80","author":"D Rades","year":"2011","unstructured":"Rades\u00a0D, Freundt\u00a0K, Meyners\u00a0T et\u00a0al (2011) Dose escalation for metastatic spinal cord compression in patients with relatively radioresistant tumors. Int J Radiat Oncol Biol Phys 80:1492\u20131497. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.04.026","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2082_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.radonc.2022.05.035","volume":"173","author":"X Chen","year":"2022","unstructured":"Chen\u00a0X, LeCompte\u00a0MC, Gui\u00a0C et\u00a0al (2022) Deviation from consensus contouring guidelines predicts inferior local control after spine stereotactic body radiotherapy. Radiother Oncol 173:215\u2013222. https:\/\/doi.org\/10.1016\/j.radonc.2022.05.035","journal-title":"Radiother Oncol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-023-02082-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-023-02082-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-023-02082-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T15:02:55Z","timestamp":1706022175000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-023-02082-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2082"],"URL":"https:\/\/doi.org\/10.1007\/s00066-023-02082-w","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,5]]},"assertion":[{"value":"8 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.J.\u00a0Redmond\u00a0has received research support, travel expenses, and honorarium for educational seminars from Accuray; research support from Canon and Elekta; participates in a\u00a0data safety monitoring committee for BioMimetix; and received travel expenses from Brainlab, Elekta, and Icotec. S.S.\u00a0Lo\u00a0is a\u00a0member of the Elekta Gamma Knife ICON Expert Group. F.R.\u00a0is a\u00a0consultant for Stryker, Brainlab and Spineart and receives royalties from Spineart. B.M.\u00a0discloses honoraria\/expenses, consulting\/advisory board, and funded research from and for Zeiss, Brainlab and Icotec. S.E.\u00a0Combs\u00a0reports grants from Deutsche Forschungsgemeinschaft; non-financial support from Deutsches Konsortium f\u00fcr Translationale Krebsforschung; consulting fees, speaker agreements, travel expenses, honoraria and non-financial support from Roche, AstraZeneca, Medac, Dr. Sennewald Medizintechnik, Elekta, Accuray, BMS, Brainlab, Daiichi Sankyo, Icotec AG, HMG Systems Engineering and Carl Zeiss Meditec AG. M.\u00a0Waltenberger, M.M.E.\u00a0Vogel, D.\u00a0Bernhardt, S.\u00a0M\u00fcnch, S.\u00a0Dobiasch, G.\u00a0Acker, M.G.\u00a0Fehlings, F.\u00a0Ringel, P.\u00a0Vajkoczy and B.\u00a0Meyer declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}